Recombinant human collagen III gel for transplantation of autologous skin cells in porcine full-thickness wounds.
Complex skin wounds, such as chronic ulcers and deep burns, require lengthy treatments and cause extensive burdens on healthcare and the economy. Use of biomaterials and cell transplantation may improve traditional treatments and promote the healing of difficult-to-treat wounds. In this study, we investigated the use of recombinant human collagen III (rhCol-III) gel as a delivery vehicle for cultured autologous skin cells (keratinocytes only or keratinocyte-fibroblast mixtures). We examined its effect on the healing of full-thickness wounds in a porcine wound-healing model. Two Landrace pigs were used for the study. Fourteen deep dermal wounds were created on the back of each pig with an 8 mm biopsy punch. Syringes containing acellular rhCol-III gel (n = 8) or rhCol-III gel with autologous keratinocytes (n = 8) or rhCol-III gel with autologous keratinocytes and fibroblasts (n = 8) were applied into wounds. Untreated wounds were used as controls for the treatment groups (n = 4). We used rhCol-III gel to manufacture a cell-delivery syringe containing autologous skin cells. In a full-thickness wound-healing model, we observed that rhCol-III gel enhances early granulation tissue formation. Interestingly, we found cell type-dependent differences in the stability of rhCol-III in vivo. Fibroblast-containing gel was effectively removed from the wound, whereas gels without cells or with keratinocytes only remained intact. Our results demonstrate that the properties of rhCol-III gel for skin cell transplantation can be significantly altered in a cell type-dependent manner.
Institute of Biomedicine, Pharmacology, University of Helsinki, Finland.|3rd Department of Surgery, Helsinki University Central Hospital, Finland.
Kristo
K
Nuutila
Institute of Biomedicine, Pharmacology, University of Helsinki, Finland.|3rd Department of Surgery, Helsinki University Central Hospital, Finland.
Matti
M
Peura
Department of Dermatology, Helsinki University Central Hospital, Finland.
Sari
S
Suomela
Institute of Biomedicine, Anatomy, University of Helsinki, Finland.
Mika
M
Hukkanen
Institute of Biomedicine, Pharmacology, University of Helsinki, Finland.|3rd Department of Surgery, Helsinki University Central Hospital, Finland.
Antti
A
Siltanen
Institute of Biomedicine, Pharmacology, University of Helsinki, Finland.|3rd Department of Surgery, Helsinki University Central Hospital, Finland.
Ari
A
Harjula
Helsinki Burn Centre, Department of Plastic Surgery, Helsinki University Central Hospital, Finland.
Jyrki
J
Vuola
Institute of Biomedicine, Pharmacology, University of Helsinki, Finland.|3rd Department of Surgery, Helsinki University Central Hospital, Finland.
Esko
E
Kankuri
D000818:Animals; D064592:Autografts; D002056:Burns / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D017690:Cell Transplantation / Q000379:methods*; D024061:Collagen Type III / Q000494:pharmacology*; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology / Q000637:transplantation*; D006801:Humans; D015603:Keratinocytes / Q000378:metabolism / Q000473:pathology / Q000637:transplantation*; D011994:Recombinant Proteins / Q000494:pharmacology; D013552:Swine; D014945:Wound Healing / Q000187:drug effects*
D024061:Collagen Type III; D011994:Recombinant Proteins
autologous; regeneration; rhCol-III; skin cells; transplantation; wound healing